Survodutide
Sources
publication, as of 2026-06-07Stale
https://pubmed.ncbi.nlm.nih.gov/42253238/
Survodutide, an investigational glucagon receptor-GLP-1 receptor dual agonist, was administered subcutaneously. At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% in the 3.6-mg group, -13.0% in the 6.0-mg group, and -5.4% in the placebo group.
N Engl J Med 2026;395:776-787, PMID 42253238, abstract
registry, as of 2026-03-12Stale
https://clinicaltrials.gov/study/NCT06066515
Protocol section, NCT06066515 SYNCHRONIZE-1, last update posted 2026-03-12
registry, as of 2026-10-29Stale
https://clinicaltrials.gov/study/NCT06077864
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT). Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 5530. Conditions Obesity. This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascul
ClinicalTrials.gov NCT06077864 protocol and results modules
registry, as of 2026-08-06Stale
https://clinicaltrials.gov/study/NCT06066528
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 755. Conditions Obesity; Diabetes Mellitus, Type 2. This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who
ClinicalTrials.gov NCT06066528 protocol and results modules
registry, as of 2026-10-30Stale
https://clinicaltrials.gov/study/NCT07850063
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 600. Conditions Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD). People can take part if their body mass index (BMI) is 27 kg/m² or higher, and they have certain heart and blood vessel
ClinicalTrials.gov NCT07850063 protocol and results modules
registry, as of 2026-10-30Stale
https://clinicaltrials.gov/study/NCT07850050
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 600. Conditions Obesity. This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause. People can join this study if they have a Body Mass Index (BMI) of 30 kg/m² or more, or if their BMI is 27 kg/m² or more and they have one
ClinicalTrials.gov NCT07850050 protocol and results modules
registry, as of 2026-10-27Stale
https://clinicaltrials.gov/study/NCT07855900
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 350. Conditions Obesity. This study is open to adults with overweight or obesity. People can join the study if they have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more with at least one weight- related health problem. Participants must not have diabetes, and they must have trie
ClinicalTrials.gov NCT07855900 protocol and results modules
registry, as of 2026-04-30Stale
https://clinicaltrials.gov/study/NCT06214741
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 307. Conditions Obesity; Overweight. This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m\^2 or higher or 24 kg/m\^2 or higher with at least 1 weight related problem can join the study. The main purpose of this s
ClinicalTrials.gov NCT06214741 protocol and results modules
registry, as of 2026-04-30Stale
https://clinicaltrials.gov/study/NCT06176365
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 274. Conditions Obesity. This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 35 kg/m² or more and at least one health problem related to their weight, or * a BMI of 27 kg/m² or more and at least two health problems related to their weight. People who have ei
ClinicalTrials.gov NCT06176365 protocol and results modules
registry, as of 2026-04-30Stale
https://clinicaltrials.gov/study/NCT06309992
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD). Overall status COMPLETED. Phases PHASE3. Lead sponsor Boehringer Ingelheim. Enrollment 218. Conditions Obesity; Non-Alcoholic SteatoHepatitis (NASH). This study is open to adults who are at least 18 years old and have * presumed or confirmed NASH together with overweight or obesity and * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² and at least one weight-related health problem. People with a history o
ClinicalTrials.gov NCT06309992 protocol and results modules
registry, as of 2023-11-02Stale
https://clinicaltrials.gov/study/NCT04667377
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Boehringer Ingelheim. Enrollment 387. Conditions Obesity. This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps peop Weight Loss of ≥ 5% of Baseline Weight at Week 46 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) 60.7 Weight Loss of ≥ 5% of Baseline Weight at Week 46 2.4 mg BI 456906 - Planned Maintenance Treatment 81.0 Weight Loss of ≥ 5% of Baseline Weight at Week 46 3.6 mg BI 456906 - Planned Maintenance Treatment 82.0 Weight Loss of ≥ 5% of Baseline Weight at
ClinicalTrials.gov NCT04667377 protocol and results modules
registry, as of 2021-03-22Stale
https://clinicaltrials.gov/study/NCT03591718
A Study to Test Different Doses of BI 456906 in Patients With Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 131. Conditions Obesity. Main objective is to investigate the tolerability of different titration schemes of BI 456906 in otherwise healthy patients with obesity/overweight, and to determine a titration scheme for future studies.
ClinicalTrials.gov NCT03591718 protocol and results modules
registry, as of 2026-03-13Stale
https://clinicaltrials.gov/study/NCT06200467
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 110. Conditions Overweight; Obesity. This study is open to adults between 18 and 55 years of age with overweight or obesity. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) has an effect on cardiac safety. When a new medicine is developed, it is important to check whether i
ClinicalTrials.gov NCT06200467 protocol and results modules
registry, as of 2025-01-22Stale
https://clinicaltrials.gov/study/NCT05751226
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 88. Conditions Healthy; Obesity. This study is open to adults between 18 and 55 years of age who are living with overweight or obesity. People with a body mass index (BMI) from 27 to 40 kg/m2 can join the study. The main purpose of this study is to find out how a medicine called BI 1820237 is tolerated by peopl
ClinicalTrials.gov NCT05751226 protocol and results modules
registry, as of 2024-08-15Stale
https://clinicaltrials.gov/study/NCT05296733
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 82. Conditions Healthy; Liver Diseases; Obesity. This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is
ClinicalTrials.gov NCT05296733 protocol and results modules
registry, as of 2026-05-12Stale
https://clinicaltrials.gov/study/NCT06745284
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 64. Conditions Obesity. This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy a
ClinicalTrials.gov NCT06745284 protocol and results modules
registry, as of 2026-06-15Stale
https://clinicaltrials.gov/study/NCT07413913
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 56. Conditions Healthy; Obesity. The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly. During study visits, the doctors collect information about participants'
ClinicalTrials.gov NCT07413913 protocol and results modules
registry, as of 2026-10-28Stale
https://clinicaltrials.gov/study/NCT07768813
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 44. Conditions Healthy; Obesity. The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product \[formulation A\]) and in a vial (test product \[formulation B2\]) in male and female trial participants who are healthy or otherwise healthy with overwei
ClinicalTrials.gov NCT07768813 protocol and results modules
registry, as of 2026-03-13Stale
https://clinicaltrials.gov/study/NCT06564441
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 34. Conditions Overweight; Obesity. This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg. The purpose of this study is to find out whether taking multiple doses of BI 456906 influe
ClinicalTrials.gov NCT06564441 protocol and results modules
registry, as of 2025-04-16Stale
https://clinicaltrials.gov/study/NCT05896384
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 32. Conditions Healthy. This study is open to women with overweight or obesity who are otherwise healthy. Women with a body mass index (BMI) from 27 to 40 kg/m2 can participate. The purpose of this study is to find out whether taking multiple doses of BI 456906 influences the amount of ethinylestradiol
ClinicalTrials.gov NCT05896384 protocol and results modules
registry, as of 2025-04-23Stale
https://clinicaltrials.gov/study/NCT06492135
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body. Overall status COMPLETED. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 30. Conditions Overweight; Obesity. This study is open to Chinese adults aged 18 to 60 with overweight or obesity. People can join the study if they have a Body Mass Index from 24 to 40.0 kg/m2. Survodutide is a medicine being developed to help people with overweight or obesity. The purpose of this study is to fin
ClinicalTrials.gov NCT06492135 protocol and results modules
registry, as of 2026-09-09Stale
https://clinicaltrials.gov/study/NCT05202353
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Boehringer Ingelheim. Enrollment 29. Conditions Obesity. This study is open to adults with obesity. People with a body mass index (BMI) in the range from 30 to 40 kg/m2 and a body weight of 70 to 150 kg can participate in the study. The purpose of this study is to find out whether treatment with a medicine called BI 456906 changes the
ClinicalTrials.gov NCT05202353 protocol and results modules